The radioprotective effect of hydroalcholic Zataria multiflora (Avishan-e shirazi) extract was investigated against genotoxicity induced by γ irradiation in human lymphocytes. Peripheral blood samples were collected from human volunteers and incubated with Z. multiflora extract at different concentrations (5, 10, and 50 μg/mL) for 1 hour. At each dose point, the whole blood was exposed in vitro to 150 cGy of cobalt-60 γ irradiation, and then the lymphocytes were cultured with mitogenic stimulation to determine number of the micronuclei in cytokinesis-blocked binucleated cells. The treatment of lymphocytes with extract showed a significant decrease in the incidence of micronuclei binucleated cells, compared with similarly irradiated lymphocytes without extract against γ irradiation. The maximum protection and decrease in frequency of micronuclei was observed at 50 μg/mL of Zataria extract by 32% reduction. High-performance liquid chromatography analysis of extract showed that it contains high amounts of thymol. Zataria extract exhibited concentration-dependent radical-scavenging activity on 1,1-diphenyl-2-picryl hydrazyl free radicals. These data have an important application for the protection of human lymphocyte from the genetic damage and side-effects induced by γ irradiation in personnel exposed to radiation.

Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A and is used for the treatment of several cancers. We labeled this monoclonal antibody with Iodine-131 (¹³¹I) and performed in vitro quality control and tumor cell growth inhibition tests. Bevacizumab was labeled with ¹³¹I using chloramine T. Radiochemical purity and stability in phosphate-buffered saline and human blood serum were determined using thin-layer chromatography and radio-sodium dodecyl sulfate-polyacrylamide gel electrophoresis, respectively, performed at different times. Cell-specific binding, internalization, and toxicity of the radiolabeled antibody were tested using the SKOV-3 ovarian cancer cell line. The biodistribution of ¹³¹I-bevacizumab was investigated using male mice. The radiochemical purity of the complex was 99% ± 0.7%. Its stability in phosphate-buffered saline and human blood serum at 48 hours postpreparation was 78% ± 1.2% and 93% ± 0.6%, respectively. (131)I-bevacizumab was significantly bound to SKOV-3. The internalization of ¹³¹I-bevacizumab was time dependent, and it was cleared from the blood after 24 hours. Significant reductions in SKOV-3 cell viability were achieved with (131)I-bevacizumab at a concentration of 500 nM. A low accumulation of ¹³¹I-bevacizumab was observed in the stomach and salivary glands after 24 hours and 48 hours. These findings indicate that the new radiolabeled antibody should be further evaluated in animals and, possibly, in humans as a new radiopharmaceutical agent for use in radioimmunotherapy for ovarian cancer.